ArticleBMC neurology2026
Characteristics of and risk factors for epilepsy after autoimmune and infectious encephalitis.
Article in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEncephalitis is associated with significant morbidity including epilepsy. Data on post-encephalitic epilepsy (PEE) incidence and optimal management remain scarce. We prospectively investigated the frequency, characteristics, and risk factors of PEE after autoimmune encephalitis (AE) and infectious encephalitis (IE) in three Austrian tertiary care hospitals over ten years. MATERIALS &
methodsWe included patients ≥ 18 years diagnosed according to internationally recognized encephalitis algorithms or verification of well-characterized antineuronal autoantibodies (AE) or pathogens (IE). Epilepsy diagnosis followed International League Against Epilepsy criteria. All available clinical data were collected from electronic patient files. A prospective follow-up was conducted via structured interviews and clinical visits. Statistical analyses included Kaplan-Meier plots, correlation analyses, and regression models.
resultsOf 149 patients, 26 (17%) had AE, 108 (73%) IE, and 15 (10%) encephalitis of unknown etiology. Prospective follow-up was achieved in 74% of cases. Median follow-up was 2304 days (IQR 1433; 3274). Acute symptomatic seizures (ASS), acute symptomatic status epilepticus and PEE are significantly more frequent in AE than in IE (p < 0.001). Antiseizure medication (ASM) use persisted in 85% of AE and 30% of IE patients at last follow-up, despite only 12% meeting PEE criteria. In both types of encephalitis, we see a shift from focal-to-bilateral semiology. Difficult-to-treat seizures during initial hospitalization correlated with PEE risk (rho = 0.317; p < 0.001). DISCUSSION: Our study provides insights into PEE characteristics, management, and prognosis. It highlights the prevalence of ASM overuse in the wake of encephalitis and provides a prognostic tool assessing the individual PEE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.